Treatment will depend on the stage of the cancer and may include surgery, chemotherapy, and radiation.
Surgery
- CYTALUX™: FDA-approved prescription medication that is given prior to surgery to adult patients who have ovarian cancer. It helps surgeons visualize ovarian cancer lesions during surgery.
- Surgery for Recurrent Ovarian Cancer Does Not Improve Survival. {study}. Findings suggest that women who have additional surgery may fare worse than those who do not.
Chemotherapy
- Cisplatin (1978)
- → Curcumin {study}
- → Melatonin {study}
- → Berberine {study}
- → Resveratrol {study}
- → Ursolic Acid {study}
- → Ashwagandha {study}
- → Bitter Melon {study}
- → Honokiol {study}
- → Low dose Naltrexone {study}
- Altretamine (1990)
- Carboplatin (1991)
- → see cisplatin
- → Vitamin D3 {study}
- Paclitaxel (Taxol)(1992)
- → I3C + EGCG {study}
- → Modified Citrus Pectin 🛈 {study┃study}
- → Feverfew {article}
- → Boswellia {study}
- → Lapachone {study}
- Topotecan (1996)
- Low dose of daily Topotecan combined with bevacizumab {ref}
- Pegylated Liposomal Doxorubicin, PLD (2000)
- Gemcitabine + Carboplatin (2006) {reduced-dose-doublet schedule}
- Bevacizumab (Avastin) + chemo platinum resistant (2014) {article phase III trial}
- Bevacizumab + chemo platinum sensitive (2016)
- → Metformin {study}
- Rucaparib (2016) PARP inhibitor {ref}
- Niraparib (2017) PARP inhibitor {clinical trial results} Data from the ENGOT-OV16/NOVA study show no difference in overall survival (OS) for patients with platinum-sensitive recurrent ovarian cancer who received poly (ADP-ribose) polymerase (PARP) inhibitor Niraparib maintenance therapy and those who did not. {ref}
- Olaparib (2018) PARP inhibitor
- → Alantolactone (selective STAT3 inhibitor) {study}
- No Overall Survival Difference With PARP Inhibitor Maintenance Therapy in Ovarian Cancer {post}
- Pembrolizumab, Bevacizumab, and Cyclophosphamide{clinical trial/article} Complete responses were observed in 7.5% of women, whereas partial responses occurred in 40% of women, and 47.5% had stable disease as a response to the treatment. In addition, the ORR was 47.5%, with 95% obtaining clinical benefit from the treatment and 25% experiencing a durable response. The median PFS throughout the trial was 10 months.
Chemotherapy vs 40 mg tamoxifen in platinum-resistant ovarian cancer: a phase III, randomized, multicentre trial (Ovaresist): chemotherapy experienced more toxicity and poorer Health-related Quality of Life compared with tamoxifen There was no difference in OS between the treatment arms.{ref}
Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer {ref}
Alternative or Complementary treatments (Integrative Therapy)
Supplements
Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin. These findings suggest that the same aspirin regimen proven to protect against cardiovascular events and several cancers could reduce the risk of ovarian cancer 20% to 34% depending on frequency and dose of use. {study}
Vitamin D {study}
Honokiol and Magnolol {study}
Amla: Emblica officinalis Extract Induces Autophagy and Inhibits Human Ovarian Cancer Cell Proliferation, Angiogenesis, Growth of Mouse Xenograft Tumors "In this study we determined that Amla extract (AE) has anti-proliferative effects on OC cells under both in vitro and in vivo conditions. We also determined the anti-proliferative effects one of the components of AE, quercetin, on OC cells under in vitro conditions. AE did not induce apoptotic cell death, but did significantly increase the expression of the autophagic proteins beclin1 and LC3B-II under in vitro conditions. Quercetin also increased the expression of the autophagic proteins beclin1 and LC3B-II under in vitro conditions. AE also significantly reduced the expression of several angiogenic genes, including hypoxia-inducible factor 1α (HIF-1α) in OVCAR3 cells. AE acted synergistically with cisplatin to reduce cell proliferation and increase expression of the autophagic proteins beclin1 and LC3B-II under in vitro conditions. AE also had anti-proliferative effects and induced the expression of the autophagic proteins beclin1 and LC3B-II in mouse xenograft tumors. Additionally, AE reduced endothelial cell antigen – CD31 positive blood vessels and HIF-1α expression in mouse xenograft tumors."
Artemisinin: https://www.ncbi.nlm.nih.gov/pubmed/30395153
Astragalus
Sulforaphane: https://www.spandidos-publications.com/ijmm/42/5/2447
Lycopene: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489781/: "Lycopene decreased the expression of the ovarian cancer biomarker, CA125. The anti-metastatic and anti-proliferative effects were accompanied by down-regulated expression of ITGA5, ITGB1, MMP9, FAK, ILK and EMT markers, decreased protein expression of integrin α5 and reduced activation of MAPK."
Green Tea: Green tea consumption enhances the survival of epithelial ovarian cancer. "There were 81 (77.9%) of 104 tea-drinkers who survived to the time of the interview, compared to only 67 women (47.9%) still alive among the 140 non-drinkers." {Study}
I3C + EGCG: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4792-9: "Long-term usage of I3C and EGCG may represent a new promising way of maintenance therapy in advanced ovarian cancer patients, which achieved better treatment outcomes."
I3C: {ref}
Baicalin https://www.ncbi.nlm.nih.gov/pubmed/29039573
Graviola {ref}
Modified Citrus Pectin
Zinc {study}
Helixor M (mistletoe) {case report}
Tripterygium Wilfordii + curcumin / milk thistle / ascorbic acid
Fucoidan
Propolis
Calcitriol {study│study│study}
DHA Dihydroartemisinin + Curcumin: {study}
Vitamin K2 {study}
Beta-Caryophyllene (copaiba){study}
Delta-Tocotrienol, a form of vitamin E derived from annatto seeds, along with Avastin (Bevacizumab) doubled the survival rate and stabilized the disease in 70% of chemotherapy-resistant ovarian cancer patients {study}
Nobiletin {study}
Epigenetic mechanisms
- Butyrate: genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells {article}
Repurposed drugs🟪
⌘ Natural PARP inhibitors
- Puerarin Sources: Kudzu Root Extract
- Chlorogenic acid Sources: Green coffee bean extract🛈
- Biochanin Sources: Red clover
- Phloretin Sources: Manchurian apricot (Prunus mandshurica)
- Hesperetin http://nutrition.merschat.com/foods-by-nutrient.cgi?Nutr_No=759
- Quercetin capers, red onions, unsweetened dark chocolate(85% cocoa), more
- Quercetin: a natural compound for ovarian cancer treatment {study}
- Niacinamide Available as a supplement study
- Naringin Grapefruit*, citrus fruit, bergamot, sour orange, tart cherries, tomatoes, cocoa, oregano, oil of oregano, water mint, Drynaria, and beans.
- Quercetin: a natural compound for ovarian cancer treatment {study}
*Eating grapefruit or drinking grapefruit juice while taking certain medications can lead to higher levels in your blood and more side effects. With some drugs, even small amounts of grapefruit can cause severe side effects. Therefore, the combination should be avoided.
⌘ HDAC Inhibition
- HDACi
- "Ovarian clear cell carcinoma (OCCC) is associated with a frequent loss in ARID1A function. ARID1A reportedly suppresses histone deacetylase (HDAC)6 in OCCC directly" {article}
- Natural product-derived therapy for gynecologic cancers (HDAC6) "pharmacological formulations encompassing “Berberine (BER), Dihydroartemisinin (DHA), and Curcumin (CUR) or their analogues, either alone or in combination with other known anticancer drugs” may be used to inhibit the progression of ARID1A-mutated ovarian cancers ". 46–70% of clear cell carcinomas and 30–46% of endometrioid carcinomas harbor ARID1A mutations. {article}
- Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High-Grade Serous Ovarian Cancer Cell Line {Ref}
- Scriptaid (HDACi) + bortezomib (proteasome inhibitor): {study} ⚠ Green tea polyphenols block the anticancer effects of bortezomib
- Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer {study}
⌘ Angiogenesis
Ovarian cancer ˃ vascular endothelial growth factor (VEGF) driven tumor
- Caffeine
- Theobromine:{study| study | article}, Foods highest in Theobromine also{pgp inhibitor}
- Ashwagandha
- Viscum album
- Curcumin
- Green tea
- Ginger
- Grape seed extract
- Ginkgo Biloba
- Magnolia officinalis
⌘ mTOR inhibition
- Vistusertib
https://www.ncbi.nlm.nih.gov/pubmed/30016392:"The study found that just over half of the ovarian cancer patients saw the size of their tumour shrink by at least 30%. It also saw an average of nearly six months progression-free survival, meaning there was no further tumour growth in this period of time. These outcomes are particularly significant as previously this type of ovarian cancer would have been resistant to all types of standard treatment."
- Curcumin
- Rapamycin
⌘ FAK inhibition
Cryptotanshinone Inhibits Ovarian Tumor Growth and Metastasis by Degrading c-Myc and Attenuating the FAK Pathway {study}
⌘ ALDH1A inhibitor
https://www.tocris.com/products/673-a_6934
⌘ MIP-1β inhibition
"macrophages produce a protein called MIP-1β, which causes the mesothelial cells to produce more of an adhesion protein called P-selectin. P-selectin, in turn, allows the cancer cells to stick." {article}⌘ HER2 overexpression
- Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. {study}
- honokiol, magnolol also downregulate P-gp expression {study}
- Danshen
- Echinacea
- Curcumin
⌘ MMP-9 overexpression
- https://www.ncbi.nlm.nih.gov/pubmed/28859117: "results suggest that the phosphorylation of STAT3 regulates MMP-9 production in ovarian cancer, which might be responsible for its invasiveness and metastasis."
⌘ CD36 downregulation
Relevant studies, articles, and reviews
- Ovarian tumors: an overview
- Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer {article}
- Flavonoids showed anticancer effects on the ovarian cancer cells: Involvement of reactive oxygen species, apoptosis, cell cycle and invasion
- Survival of patients with advanced and recurrent ovarian cancer treated using integrative medicine in Malaysia: A case series
- Have we given up on a cure for ovarian cancer? {article}
- Hypoxia-inducible factor-1α promotes cell survival during ammonia stress response in ovarian cancer stem-like cells
- Overcoming Stage IV Ovarian Cancer: A Life Well-Lived
- miR-450a acts as a tumor suppressor in ovarian cancer by regulating energy metabolism
- Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells
- Epigenetic therapy for ovarian cancer: promise and progress
- ARID1A-mutated ovarian cancers depend on HDAC6 activity
- https://www.upmc.com/media/news/031219-targeting-stem-cells-ovarian-ca
- https://www.ncbi.nlm.nih.gov/pubmed/26344206
- https://www.hindawi.com/journals/jna/2010/157591/
- https://www.ncbi.nlm.nih.gov/pubmed/29399200
- https://www.spandidos-publications.com/10.3892/ijo.2015.3304
- https://www.cancertreatmentsresearch.com/phlorizinphloretin-a-strong-glucose-transport-inhibitor/
- https://www.lifeextension.com/vitamins-supplements/item01625/applewise
- https://reference.medscape.com/drug/lynparza-olaparib-999934
- Signaling Mechanism of Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Inflammatory Diseases
- Metastasis enablers: Findings could unlock new ovarian cancer treatments
- How statins could be more effective in the treatment of ovarian cancer
- High-Dose Vitamin C Helps Prevent Recurrence of Stage IV Ovarian Cancer: A Case Report
- How We Treat Ovarian Cancer (Dana-Farber Cancer Institute)
- Approved Blood Cancer Inhibitors May Be Effective Therapy for Ovarian Tumors, Study Finds
- Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis
- Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment
No comments:
Post a Comment